The positive predictive value of O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment
- 23 January 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 88 (1), 27-35
- https://doi.org/10.1007/s11060-008-9526-4
Abstract
Objective To explore prospectively the positive predictive value of O-(2-[18F]fluoroethyl)-l-tyrosine (FET)–PET in selected patients with a magnetic resonance imaging (MRI)-based suspicion of a glioma recurrence or progression. Methods Patients with a supratentorial glioma (initial World Health Organization (WHO) grade II, III or IV) were considered eligible if they had both an MRI-(new/progressive contrast-enhancing lesion) and FET–PET-based diagnosis of a recurrence/progression after various forms and combinations of irradiation and chemotherapy. Criterion for tumour recurrence/progression in FET–PET was a standardized uptake value (SUVmax)/Background (BG) ratio of >2.0 in the late uptake phase. All patients underwent multimodal (MRI, FET–PET) imaging-guided stereotactic biopsy. The positive predictive value was defined as the proportion of MRI and FET–PET findings indicating glioma recurrence/progression that also tested positive for tumour recurrence/progression after stereotactic biopsy. Results Thirty-one patients with initially WHO grade II (17), WHO grade III (6), and grade IV glioma (8) were included. In 26 patients FET–PET results indicating tumour recurrence/progression were concordant with the biopsy results. In five patients histopathologic evaluation failed to reveal a “vital” tumour. FET–PET findings were also discordant with the radiographic and clinical follow-up in these five patients. The positive predictive value of FET–PET was 84%. Conclusion The positive predictive value of FET–PET using the standard ratio method is high, but not high enough to replace stereotactic biopsy in this highly selected study cohort. Whether the calculation of FET uptake in the early phase and/or the evaluation of uptake kinetics will improve the positive predictive value of FET–PET deserves prospective evaluation.Keywords
This publication has 42 references indexed in Scilit:
- Distinction Between Recurrent Glioma and Radiation Injury Using Magnetic Resonance Spectroscopy in Combination With Diffusion-Weighted ImagingInternational Journal of Radiation Oncology*Biology*Physics, 2007
- O-(2-[18F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applicationsNuclear Medicine and Biology, 2006
- Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-l-tyrosine and magnetic resonance spectroscopyJournal of Neurosurgery, 2005
- O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomasBrain, 2005
- Comparative follow-up of enhancement phenomena with MRI and Proton MR Spectroscopic Imaging after intralesional immunotherapy in glioblastomaCentral European Neurosurgery, 2002
- Survival Results from a Phase I Study of Etanidazole (SR2508) and Radiotherapy in Patients with Malignant GliomaInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful?Journal of Neurosurgery, 1995
- The use of PET in evaluating patients with primary brain tumours: is it useful?Journal of Neurology, Neurosurgery & Psychiatry, 1995
- Sequential morphological changes in the dog brain after interstitial iodine- 125 irradiationNeurosurgery, 1983
- Sequential Morphological Changes in the Dog Brain after Interstitial Iodine-125 IrradiationNeurosurgery, 1983